Gni Group Ltd. · TSE:2160

Gni — Q3 2020 Earnings Presentation

11 slides from Gni's earnings presentation, Nov 16, 2020

  1. Slide 1: GNI Group Ltd. Q3 FY2020 Financial Results

    GNI Group Ltd. Q3 FY2020 Financial Results Corporate Presentation November 16, 2020 We Bring New Hope to Patients Securities Code: 2160

  2. Slide 2: Forward-looking Statements

    We Bring New Hope to Patients Forward-looking Statements This presentation contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. (GNI Group). Any statements contained herein that pertain to future operating performance and that are not historic facts are for

  3. Slide 3: FY2020 – Q3 Highlights

    We Bring New Hope to Patients FY2020 – Q3 Highlights Continuous growth despite global pandemic We continued executing our business plan smoothly in Q3 and achieved year over year revenue and profit growth, while investing heavily into R&D for our future growth. Consolidated revenue increases by 30.4

  4. Slide 4: FY2020-Q3 Consolidated Financial Results Comparison (YoY)

    We Bring New Hope to Patients FY2020-Q3 Consolidated Financial Results Comparison (YoY) Million yen : Amounts of less than one million yen are rounded down FY2019 FY2020 Statement of Income Jan.-Sept. Jan.-Sept. Change Revenue & Gross Profit Revenue 5,333 6,953 30.4% Continued strong performance of

  5. Slide 5: Revenue Growth Trend

    We Bring New Hope to Patients Revenue Growth Trend Index:2017 Q1 Revenue =100 Started New production 800 factory construction for BC* Strong sales trend of Etuary® Contributed additional sales 735 700 Achieved a key milestone with and profits to GNI Group’s 607 the inclusion of Etuary® in positive o

  6. Slide 6: Development: Pipeline Update

    We Bring New Hope to Patients Development : Pipeline Update Product - Indication Origin Phase I Phase II Phase III Latest Status Etuary® (China) - Connective Tissue Disease Associated Dual Phase III clinical trials ongoing. Proceeding smoothly despite the Proprietary Interstitial Lung Disease (CTD-I

  7. Slide 7: F351 - The Key to our Future

    We Bring New Hope to Patients F351-The Key to our Future Completion of Phase 2 Clinical Trials of F351  F351 Phase II clinical trials for the treatment of HBV induced liver fibrosis met primary endpoints of reduction of liver fibrosis score (Ishak Score)  F351 showed good safety profile among live

  8. Slide 8: Beijing Continent's Growth Path

    We Bring New Hope to Patients Beijing Continent’s Growth Path ■Preparation for bigger capacity Acquired the land in Hebei Province (approximately 13,000 square meters) adjacent to the current factory - Strong sales trend of Etuary® expected - F351 production ■Expanded pipeline GNI Group transferred

  9. Slide 9: IR Hot Topics (Q&A Session in J Page)

    We Bring New Hope to Patients IR Hot Topics (Q&A Session in J Page)  Timeline for F351 NDA and Phase III trials We are actively preparing for consulting with CDE of NMPA as explained previously. All decisions are up to CDE. Although we cannot decide the timeline, we will disclose any material progr

  10. Slide 10: IR Hot Topics (Q&A Session in J Page)

    We Bring New Hope to Patients IR Hot Topics (Q&A Session in J Page)  Why did we have to transfer it from SG to BC?(the purpose) As part of future NDA application, BC as the only manufacture center in whole GNI Group, need to have the IP.  How much did BC pay for this matter? (the value of IP) Tran

  11. Slide 11: Contact Information

    We Bring New Hope to Patients Contact Information infojapan@gnipharma.com © 2020 GNI Group Ltd. All rights reserved 11

GNI Group — Q3 2020 Earnings Presentation on 6ix